Johnson & Johnson in Advanced Talks to Buy Ollin Biosciences
FROM THE WIRE · FINANCE.YAHOO.COM
Johnson & Johnson (JNJ) is back in focus after reports it is in advanced talks to buy eye drug developer Ollin Biosciences in a deal valued at up to US$3.4b. The Ollin Biosciences headlines land on top of a strong run for Johnson & Johnson, with the share price at US$285.75 and…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralA deal valued at up to $3.4 billion is relevant for pharma but has limited impact on the large group.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01According to reports, J&J is in advanced talks to buy Ollin Biosciences.
- 02The deal is valued at up to $3.4 billion.
- 03The share price is $285.75 with a 37.81% year-to-date gain.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets